Analysis of durability of response to thalidomide treatment for relapsed myeloma patients

被引：3

作者：

Myers, B ^{[1
]}

Dolan, G ^{[1
]}

机构：

[1] Univ Nottingham Hosp, Queens Med Ctr, Dept Clin & Lab Haematol, Nottingham NG7 2UH, England

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2002年 / 118卷 / 01期

关键词：

thalidomide; myeloma; therapy; duration;

D O I：

10.1046/j.1365-2141.2002.03576_4.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：347 / 347

页数：1

共 50 条

[41] Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide
Teresa Cibeira, Maria
Fernandez de Larrea, Carlos
Navarro, Alfons
Diaz, Tania
Fuster, Dolors
Tovar, Natalia
Rosinol, Laura
Monzo, Mariano
Blade, Joan
LEUKEMIA RESEARCH, 2011, 35 (09) : 1178 - 1183
[42] Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma
Ludwig, Heinz
Poenisch, Wolfram
Knop, Stefan
Egle, Alexander
Schreder, Martin
Lechner, Daniel
Hajek, Roman
Gunsilius, Eberhard
Krenosz, Karl Jochen
Petzer, Andreas
Weisel, Katja
Niederwieser, Dietger
Einsele, Hermann
Willenbacher, Wolfgang
Melchardt, Thomas
Greil, Richard
Zojer, Niklas
BRITISH JOURNAL OF CANCER, 2019, 121 (09) : 751 - 757
[43] Treatment of myeloma patients relapsed after frontline autologous stem cell transplantation with the association of thalidomide, dexamethasone and zoledronate.
Musto, P
Bodenizza, C
Falcone, A
Sanpaolo, G
Cascavilla, N
Melillo, L
Dell'Olio, M
La Sala, A
Mantuano, S
Nobile, M
Scalzulli, PR
Greco, MM
Carella, AM
Beltrami, G
Carella, AM
BLOOD, 2003, 102 (11) : 382B - 382B
[44] Usefulness of low-dose thalidomide for Japanese patients with refractory and relapsed multiple myeloma
Kanamori, H.
Hashino, S.
Takahashi, S.
Onozawa, M.
Kahata, K.
Kondo, T.
Asaka, M.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[45] Phase II and pharmacokinetic study of thalidomide in Japanese patients with relapsed/refractory multiple myeloma
Hirokazu Murakami
Kazuyuki Shimizu
Morio Sawamura
Kenshi Suzuki
Isamu Sugiura
Hiroshi Kosugi
Chihiro Shimazaki
Masafumi Taniwaki
Masahiro Abe
Toshiyuki Takagi
International Journal of Hematology, 2009, 89 : 636 - 641
[46] A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma
Prince, HM
Mileshkin, L
Roberts, A
Ganju, V
Underhill, C
Catalano, J
Bell, R
Seymour, JF
Westerman, D
Simmons, PJ
Lillie, K
Milner, AD
Di Iulio, J
Zeldis, JB
Ramsay, R
CLINICAL CANCER RESEARCH, 2005, 11 (15) : 5504 - 5514
[47] Phase II and pharmacokinetic study of thalidomide in Japanese patients with relapsed/refractory multiple myeloma
Murakami, Hirokazu
Shimizu, Kazuyuki
Sawamura, Morio
Suzuki, Kenshi
Sugiura, Isamu
Kosugi, Hiroshi
Shimazaki, Chihiro
Taniwaki, Masafumi
Abe, Masahiro
Takagi, Toshiyuki
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2009, 89 (05) : 636 - 641
[48] Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma
Sidra, Gamal
Williams, Cathy D.
Russell, Nigel H.
Zaman, Sonya
Myers, Bethan
Byrne, Jennifer L.
HAEMATOLOGICA, 2006, 91 (06) : 862 - 863
[49] Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration
Cibeira, M. Teresa
Rosinol, Laura
Ramiro, Laia
Esteve, Jordi
Torrebadell, Montserrat
Blade, Joan
EUROPEAN JOURNAL OF HAEMATOLOGY, 2006, 77 (06) : 486 - 492
[50] Thalidomide response in African American patients with multiple myeloma.
Jajeh, A
Catchatourian, R
Tamkus, D
Osafo, D
Zalzaleh, G
Yim, B
BLOOD, 2005, 106 (11) : 370B - 370B

← 1 2 3 4 5 →